Ziegler 1972a.

Methods	Randomised, parallel group, single‐site trial (Uganda). Method of randomisation: unclear. Allocation concealment: unclear. ITT: no. Withdrawals: stated.
Participants	Baseline characteristics: sample size: 41 participants, 27 were evaluable for the study. Age range: 3 to 25 years. Tumour staging: Ziegler. Diagnosis: histopathology. Entry criteria: stages III or IV disease, untreated, histopathologic diagnosis. Exclusion criteria: not stated.
Interventions	Multiple doses of C versus the TRIKE regimen (sequential regimen using C, O, MTX and Ara‐C). Follow‐up: participants followed up until death.
Outcomes	Relapse. Remission. Overall survival.
Notes	2:1 allocation was used in randomisation. Full text publication. Randomisation rating: B. Withdrawal bias rating: C. Study type: remission induction.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	"randomised by stage".
Allocation concealment (selection bias)	Unclear risk	Not described.
Blinding (performance bias and detection bias) All outcomes	Unclear risk	Not described.
Incomplete outcome data (attrition bias) All outcomes	Low risk	Nature and frequency of relapse was reported

AD: adriamycin (doxorubicin) 
 Ara‐C: cytosine arabinoside 
 BCG: Bacille‐Calmette‐Guerin 
 BL: Burkitt lymphoma 
 BLL: Burkitt‐like lymphoma 
 C: cyclophosphamide 
 CNS: central nervous system 
 COM: cyclophosphamide, oncovin and methotrexate 
 COMP: cyclophosphamide, oncovin, methotrexate and prednisolone 
 Gy: Gray unit (SI unit of absorbed radiation) 
 HYD: hydrocortisone 
 IT: intrathecal 
 ITT: intention‐to‐treat analysis 
 IV: intravenous 
 MTX: methotrexate 
 NHL: non‐Hodgkin's lymphoma 
 O: oncovin (vincristine) 
 P: prednisolone 
 SNCCL: small non‐cleaved cell lymphoma 
 TF: transfer factor